South Korea · Delayed Price · Currency is KRW OliX Pharmaceuticals Company Description
OliX Pharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.
The company's products pipeline includes OLX101 for skin scar; OLX102 for skin whitening; OLX103, an atopic dermatitis product; OLX104 for hair loss; OLX105, an anti-wrinkle product; and OLX106 for diabetic foot ulcer.
Its products pipeline also comprise OLX301 for age-related macular degeneration retinal fibrosis; OLX304 for retinitis pigmentosa; OLX201 for lung fibrosis; OLX202 for asthma; OLX203 for influenza; OLX401 for neuropathic pain; OLX701 for liver fibrosis; and OLX701 for cancer immunotherapy.
The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.
OliX Pharmaceuticals, Inc. was founded in 2010 and is based in Suwon, South Korea.
| Country | South Korea |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dong-Ki Lee |
Contact Details
Address: Suite 1014 Suwon-si South Korea | |
| Phone | 82 3 1779 8400 |
Stock Details
| Ticker Symbol | 226950 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| ISIN Number | KR7226950004 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dong-Ki Lee | Chief Executive Officer |
| Jin Kim Young | Chief Financial Officer |